Last reviewed · How we verify
Placebo to ZOSTAVAX™
This is a placebo control arm in a clinical trial comparing against ZOSTAVAX, a live attenuated varicella-zoster virus vaccine designed to prevent herpes zoster (shingles) in older adults.
This is a placebo control arm in a clinical trial comparing against ZOSTAVAX, a live attenuated varicella-zoster virus vaccine designed to prevent herpes zoster (shingles) in older adults. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older.
At a glance
| Generic name | Placebo to ZOSTAVAX™ |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Vaccine (live attenuated) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as the inactive control comparator in Phase 3 trials of ZOSTAVAX. ZOSTAVAX itself is a live attenuated vaccine that stimulates cell-mediated and humoral immune responses against varicella-zoster virus to reduce the incidence and severity of herpes zoster and post-herpetic neuralgia in immunocompetent adults aged 50 years and older.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
Common side effects
- Injection site erythema
- Injection site swelling
- Injection site pain
- Headache
- Myalgia
Key clinical trials
- Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062) (PHASE3)
- Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ (PHASE4)
- ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) (PHASE4)
- ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED) (PHASE2)
- ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) (PHASE3)
- Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) (PHASE3)
- A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2) (PHASE1)
- A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to ZOSTAVAX™ CI brief — competitive landscape report
- Placebo to ZOSTAVAX™ updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI